GRI BIO GRI is a dynamic clinical-stage biotechnology company at the forefront of revolutionizing healthcare through groundbreaking scientific advancements. The company is focused on fundamentally changing how inflammatory, fibrotic and autoimmune diseases are treated.
When the body’s immune system is working abnormally, it can lead to chronic inflammation that is extremely damaging. Two of the most recognized inflammatory diseases are IPF, or Idiopathic Pulmonary Fibrosis, and Lupus. IPF currently has no cure and its TAM is estimated to be just shy of $4 billion.
The company has several promising therapies currently in the development pipeline that address these debilitating diseases.
Learn more here:
Featured photo by Hal Gatewood on Unsplash.
This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
—
The clinical-stage biotechnology company, GRI BIO (NASDAQ:GRI), is dedicated to revolutionizing healthcare by advancing scientific discoveries. They are specifically focused on transforming the treatment of inflammatory, fibrotic, and autoimmune diseases.
Abnormal functioning of the immune system can lead to chronic and destructive inflammation in the body. Two well-known inflammatory diseases are Idiopathic Pulmonary Fibrosis (IPF) and Lupus. IPF, which currently lacks a cure, has an estimated Total Addressable Market (TAM) of nearly $4 billion.
GRI BIO is actively developing several promising therapies to target these debilitating diseases. They have a robust pipeline of potential treatments that show great potential.
To learn more about GRI BIO and their groundbreaking work, click here.
Watch the video below to gain additional insights:
[Watch Video](https://www.youtube.com/watch?v=WZOdCpSrveE)
Featured photo by Hal Gatewood on Unsplash.
Please note that this article contains sponsored content and should be considered for informational purposes only, not as investment advice.
© 2023 Benzinga.com. All rights reserved. Benzinga does not provide investment advice.
